Selective estrogen receptor modulators (SERMs) are synthetic compounds that bind the estrogen receptor (alpha or beta) and exert tissue-dependent agonist or antagonist effects, altering nuclear DNA transcription and downstream protein synthesis; this mechanism underlies their use in estrogen receptor-positive breast cancer (tamoxifen) and infertility/ovulation induction (clomiphene citrate). Aromatase inhibitors represent a mechanistically distinct hormonal therapy class, blocking the aromatase enzyme that converts androgens to estrogens within the steroidogenesis pathway, and are indicated in postmenopausal patients as opposed to SERMs' applicability in premenopausal, reproductively capable patients. This belongs to the domain of endocrine pharmacology/gynecologic oncology, linking estrogen receptor signaling mechanism to differential drug class indication based on menopausal status and receptor-tissue specificity.
Selective estrogen receptor modulators (SERMs) are synthetic compounds that bind the estrogen receptor (alpha or beta) and exert tissue-dependent agonist or antagonist effects, altering nuclear DNA t…